Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

To evaluate the dose-response relationship of the recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11-h serum glucose profiles.
Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Issue number7
Pages (from-to)639-43
Number of pages5
Publication statusPublished - 2011

    Research areas

  • Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Infusions, Subcutaneous, Male, Middle Aged, Peptide Fragments, Placebos, Postprandial Period

ID: 40246465